WO2003006441A1 - Crystalline thiazine oxazolidinones - Google Patents
Crystalline thiazine oxazolidinones Download PDFInfo
- Publication number
- WO2003006441A1 WO2003006441A1 PCT/US2002/021779 US0221779W WO03006441A1 WO 2003006441 A1 WO2003006441 A1 WO 2003006441A1 US 0221779 W US0221779 W US 0221779W WO 03006441 A1 WO03006441 A1 WO 03006441A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal
- oxazolidin
- oxo
- dioxido
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to crystals of N-( ⁇ (5S)-3-[4-(l,l-dioxido-4- thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl) acetamide and methods for isolation of such crystals.
- Oxazolidinone antibacterial agents are a novel synthetic class of antimicrobials with potent activity against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, gram-negative aerobic bacteria such as H. influenzae and M. catarrhalis, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium avium.
- gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci
- gram-negative aerobic bacteria such as H. influenzae and M. catarrhalis
- anaerobic organisms such as bacteroides and clostridia species
- acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium avium.
- oxazolidinones generally inhibit to some extent monoamine oxidase (MAO), the enzyme responsible for preventing acute blood pressure elevation by the endogenous and dietary amine, tyramine, and other sympathomimetic amines. Accordingly, there is a demand to discover oxazolidinone antibiotics which possess minimum MAO inhibitory activity to eliminate the related side effects from potential drug-drug interactions. There also exists a need for oxazolidinone antibiotics having improved antimicrobial activity, low toxicity, and adequate stability.
- MAO monoamine oxidase
- N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide is a thiazine oxazolidinone having the following structure:
- N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide is disclosed in PCT International Publication Number WO 01/98297 (Barbachyn et al.). Although the preparation of the thiazine oxazolidinone is disclosed, the specification is silent as to the isolation and nature of crystal forms of the agent. Moreover, there exists a need for crystalline forms of such materials that have superior chemical and/or physical properties that are useful in drug delivery applications.
- the present invention provides an anhydrous crystal including N-( ⁇ (5S)-3-[4-( l,l-dioxido-4-thiomorpholinyl)-3 ,5- difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide, which has the structure:
- the crystal has a melting point of at least about 170°C, more preferably at least about 180°C, and most preferably at least about 187°C.
- the thiazine oxazolidinone is stable in a bulk drug stability test at 56°C and 75% relative humidity for at least 25 days, and more preferably at 70°C and 75% relative humidity for at least 60 days.
- the present invention provides a crystal including N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide including at most about 1% by weight water, preferably at most about 0.5% by weight water, and most preferably at most about 0.1% by weight water.
- the N-( ⁇ (5S)-3-[4-(l,l-dioxido-4- thiomo ⁇ holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ - methyl)acetamide is stable in a bulk drug stability test at 56°C and 75% relative humidity for at least 25 days, and more preferably at 70°C and 75% relative humidity for at least 60 days.
- the present invention provides a crystal including N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]- 2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide having orthorhombic space group symmetry P2A 2 ⁇ .
- the present invention provides a crystal including
- the present invention provides a crystal including
- the present invention provides a crystal including N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]- 2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide, wherein the atomic positions of the atoms of the N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]- 2-oxo- 1 ,3-oxazolidin-5-yl ⁇ methyl)acetamide are defined by a set of points having a root mean square deviation of less than about 0.1 A from the structure coordinates listed in Table 1.
- the atomic positions of the atoms are defined by the structure coordinates listed in Table 1.
- the present invention provides a crystal including N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]-
- 2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide having characteristic diffraction peaks at about 21.9, 21,4, and 16.1 degrees two-theta in an X-ray powder diffraction pattern.
- the crystal has characteristic diffraction peaks at about 29.5, 21.9, 21,4, 18.4, 16.1, and 9.2 degrees two-theta in an X-ray powder diffraction pattern. More preferably, the crystal has the characteristic diffraction peaks in an X-ray powder diffraction pattern as listed in Table 5.
- the present invention provides a solvated crystal including N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5- difluorophenyl]-2-oxo- l,3-oxazolidin-5-yl ⁇ methyl)acetamide, wherein the solvate includes a solvent selected from the group consisting of tetrahydrofuran, acetone, ethyl acetate, acetonitrile, methanol, ethanol, propanol, isopropanol, and combinations thereof.
- the present invention provides a crystal including
- N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]- 2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide having characteristic diffraction peaks at about 18.9 and 6.3 degrees two-theta in an X-ray powder diffraction pattern.
- the crystal has characteristic diffraction peaks at about 19.2, 18.9, 16.4, 9.6, and 6.3 degrees two-theta in an X-ray pov/der diffraction pattern. More preferably, the crystal has the characteristic peaks in an X-ray powder diffraction pattern as listed in Table 2, Table 3, Table 4, or combinations thereof.
- the present invention provides a method of isolating an anhydrous crystal including thiazoline oxazolidinone including cooling an aqueous solution of a solvate including N-( ⁇ (5S)-3-[4-(l,l-dioxido-4- thiomo ⁇ holinyl)-3,5-difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ - methyl)acetamide to give the anhydrous crystal including the thiazoline oxazolidinone.
- the solvate includes an organic solvent, and more preferably a non-halogenated solvent.
- the aqueous solution further includes a water miscible organic solvent, and preferably a non-halogenated solvent.
- the present invention provides a method of isolating a solvated thiazoline oxazolidinone including cooling a composition including N-( ⁇ (5S)-3-[4-(l ,l-dioxido-4-thiomo ⁇ holinyl)- 3,5-difluorophenyl]-2-oxo- l,3-oxazolidin-5-yl ⁇ methyl)acetamide and an organic solvent selected from the group consisting of tetrahydrofuran, acetone, ethyl acetate, acetonitrile, methanol, ethanol, propanol, isopropanol, and combinations thereof, to give the solvated thiazoline oxazolidinone.
- the medium further includes water.
- the present invention provides a method of isolating an anhydrous crystal including N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)- 3,5-difluorophenyl]-2- oxo-1 ,3-oxazolidin-5-yl ⁇ methyl)acetamide including inducing crystallization of N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)- 3,5-difiuorophenyl]-2- oxo- 1 ,3-oxazolidin-5-yl ⁇ methyl)acetamide from a medium including methanol and methylene chloride. Definitions
- water miscible means capable of being mixed with or dissolved in water at all proportions.
- anhydrous crystalline refers to a crystal that does not contain substantial amounts of water. The water content can be determined by methods known in the art including, for example, Karl Fischer titrations.
- an anhydrous crystalline form contains at most about 1% by weight water, more preferably at most about 0.5% by weight water, and most preferably at most about 0.1 % by weight water.
- solvate and “solvated crystal” are used interchangeably and refer to a crystal that includes a solvent molecule.
- stable in bulk drug stability tests means that at least about 90% by weight, preferably at least about 95% by weight, and more preferably at least about 99% by weight of the bulk drug remains unchanged after storage under the indicated conditions for the indicated time.
- FIGURES Figure 1 is an illustration of a ball and stick model representing the crystal structure coordinates of anhydrous crystalline N-( ⁇ (5S)-3-[4-(l,l-dioxido-4- thiomo ⁇ holinyl)-3,5-difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetami de as listed in Table 1.
- N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide is a thiazine oxazolidinone having the following structure:
- N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide can be prepared by standard synthetic procedures including, for example, those described in PCT International Publication Number WO 01/98297 (Barbachyn et al.), in which the thiazine oxazolidinone was isolated as a white solid, for example, by concentrating the thiazine oxazolidinone from a solution that included methanol and methylene chloride.
- thiazine oxazolidinone can be isolated as a white, crystalline, odorless solid in either a solvated or an anhydrous crystalline form.
- Solvated crystalline forms appear to undergo a conversion to an anhydrous crystalline form at about 100°C, thus providing a useful method for producing an anhydrous crystalline form.
- the present invention provides intermediates and methods for isolating an anhydrous crystalline form of N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)- 3,5-difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide.
- the anhydrous crystalline form shows improved properties in comparison to the solvated crystalline form.
- X-ray diffraction data was collected on a single crystal of the anhydrous crystalline form of N-( ⁇ (5S)-3-[4-( 1,1 -dioxido-4thiomo ⁇ holinyl)-3,5- difluorophenyl]-2-oxo-l,3-oxazolidin-5-y] ⁇ methyl)acetamide, and the structure was solved by standard crystallographic techniques.
- Table 1 lists atomic structure coordinates derived by x-ray diffraction of a crystal of N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide having orthorhombic space group symmetry P2 j 2 j 2 j .
- Column 2 lists a number for the atom in the structure.
- Column 3 lists the element whose coordinates are measured. The first letter in the column defines the element.
- Columns 5-7 list the crystallographic coordinates X, Y, and Z, respectively.
- the crystallographic coordinates define the atomic position of the element measured.
- Column 8 lists an occupancy factor that refers to the fraction of the molecules in which each atom occupies the position specified by the coordinates. A value of "1" indicates that each atom has the same conformation, i.e., the same position, in all molecules of the crystal.
- Column 9 lists a thermal factor "B” that measures movement of the atom around its atomic center.
- structure coordinates refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms (scattering centers) of a human beta secretase complex in crystal form.
- the diffraction data are used to calculate an electron density map of the repeating unit of the crystal.
- the electron density maps are then used to establish the positions of the individual atoms of the thiazine oxazolidinone.
- Slight variations in structure coordinates can be generated by mathematically manipulating the thiazine oxazolidinone structure coordinates.
- the structure coordinates set forth in Table 1 could be manipulated by crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above.
- modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of atoms, or other changes in any of the components that make up the crystal could also yield variations in structure coordinates. Such slight variations in the individual coordinates will have little effect on overall shape.
- the crystal structures of those portions of the two molecules are substantially identical, within acceptable error.
- Particularly preferred structurally equivalent molecules or molecular complexes are those that are defined by the entire set of structure coordinates listed in Table 1 ⁇ a root mean square deviation from the conserved backbone atoms of those amino acids of less than about 0.1 A. More preferably, the root mean square deviation is at most about O.OlA, and even more preferably, at most about O.OOlA.
- root mean square deviation means the square root of the arithmetic mean of the squares of the deviations. It is a way to express the deviation or variation from a trend or object.
- root mean square deviation defines the variation in the backbone of a compound from the backbone of the thiazine oxazolidinone defined by the structure coordinates described herein.
- FIG. 1 The three dimensional structure of the thiazine oxazolidinone is illustrated in Figure 1 with a ball and stick model representing the crystal structure coordinates of anhydrous crystalline N-( ⁇ (5S)-3-[4-(l,l-dioxido-4- thiomo ⁇ holinyl)-3,5-difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ - methyl)acetamide as listed in Table 1.
- Crystalline organic compounds consist of a large number of atoms that are arranged in a periodic array in three-dimensional space.
- the structural periodicity normally manifests distinct physical properties, such as sha ⁇ , explicit spectral features by most spectroscopic probes (e.g., X-ray diffraction, infrared and solid state NMR).
- X-ray diffraction X-ray diffraction
- Crystals yield explicit diffraction maxima which arise at specific angles consistent with the lattice inte ⁇ lanar spacings, as predicted by Bragg's law.
- amo ⁇ hous materials do not possess long-range order. They often retain additional volume between molecules, as in the liquid state.
- Amo ⁇ hous solids normally unveil a featureless XRD pattern with broad, diffuse halos because of the absence of the long range order of repeating crystal lattice.
- Powder X-ray diffraction has been reportedly been used to characterize different crystal forms of organic compounds (e.g., compounds useful in pharmaceutical compositions). See, for example, U.S. Pat. Nos. 5,504,216
- Crystalline materials are preferred in many pharmaceutical applications. Crystalline forms are thermodynamically more stable than amo ⁇ hous forms of the same substance. This thermodynamic stability is reflected in the lower solubility and improved physical stability of the crystalline form.
- the regular packing of the molecules in the crystalline solid denies the inco ⁇ oration of chemical impurities. Hence crystalline materials generally possess higher chemical purity than their amo ⁇ hous counte ⁇ arts.
- the packing in the crystalline solid constrains the molecules to well defined lattice positions and reduces the molecular mobility that is the prerequisite for chemical reactions.
- crystalline solids with very few notable exceptions, are chemically more stable than amo ⁇ hous solids of the same molecular composition.
- the crystalline forms of N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5- difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide disclosed in the present application possess one or more of the advantageous chemical and/or physical properties disclosed herein.
- the crystalline forms of N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)- 3,5-difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide disclosed in the present application have distinct powder X-ray diffraction profiles.
- the anhydrous crystalline form of the thiazine oxazolidinone can be distinguished from the solvated forms of the thiazine oxazolidinone disclosed herein by the presence of characteristic diffraction peaks.
- Characteristic diffraction peaks as used herein are peaks selected from the most intense peaks of the observed diffraction pattern.
- the characteristic peaks are selected from about 20 of the most intense peaks, more preferably from about 10 of the most intense peaks, and most preferably from about 5 of the most intense peaks in the diffraction pattern.
- an anhydrous crystalline N-( ⁇ (5S)-3-[4-(l,l-dioxido-4- thiomo ⁇ holinyl)-3,5-difluorophenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetami de has characteristic diffraction peaks at about 21.9, 21,4, and 16.1 degrees two- theta, more preferably at about 29.5, 21.9, 21,4, 18.4, 16.1, and 9.2 degrees two- theta, and most preferably has the characteristic diffraction peaks as listed in Table 5.
- a solvated crystalline N-( ⁇ (5S)-3-[4-(l,l-dioxido-4- thiomo ⁇ holinyl)-3,5-difluorophenyl]-2-oxo- 1 ,3-oxazolidin-5-yl ) methyl) acetami de has characteristic diffraction peaks at about 8.9 and 6.3 degrees two-theta, more preferably at about 19.2, 18.9, 16.4, 9.6, and 6.3 degrees two-theta, and most preferably has the characteristic diffraction peaks as listed in Table 2, Table 3, Table 4, or combinations thereof.
- the anhydrous crystalline form of the thiazine oxazolidinone may be isolated by inducing crystallization of a solvated form of the thiazine oxazolidinone from an aqueous solution.
- the aqueous solution includes water and a water miscible organic solvent.
- the water miscible organic solvent is non-chlorinated.
- Useful water miscible organic solvents include, for example, tetrahydrofuran (THF), acetone, acetonitrile, and alcohols (e.g., methanol, ethanol, propanol, and isopropanol (IPA or 2- propanol)).
- Preferred water miscible organic solvents include, for example, tetrahydrofuran, acetone, ethanol, and methanol. More preferred water miscible organic solvents include, for example, tetrahydrofuran and methanol.
- the aqueous solution preferably includes a water miscible organic solvent, more preferably at least about 10% by weight water miscible organic solvent, and most preferably at least about 25% by weight water miscible organic solvent.
- the aqueous solution preferably includes at most about 50% by weight water miscible organic solvent, and more preferably at most about 33% by weight water miscible organic solvent.
- the aqueous solution preferably includes at least about 2% of the thiazine oxazolidinone, and more preferably at least about 5% of the thiazine oxazolidinone.
- the aqueous solution preferably includes at most about 10% of the thiazine oxazolidinone, and more preferably at most about 6% of the thiazine oxazolidinone.
- the anhydrous crystalline form of the thiazine oxazolidinone is preferably induced to crystallize by cooling the aqueous solution.
- the aqueous solution is initially at about the reflux temperature of the aqueous solution.
- the aqueous solution is cooled to a temperature of about 0°C to 10°C.
- the cooling rate is maintained at a rate of at least about 2°C/hour, and more preferably at least about 5°C/hour.
- the cooling rate is maintained at a rate of at most about 20°C/hour, more preferably at most about 15°C/hour, and most preferably at most about 10°C/hour.
- the cooling rate does not need to be maintained at a constant rate throughout the cooling cycle, but can be varied as desired.
- seeding with crystals of the anhydrous form may be used if desired.
- seed crystals are added to the aqueous solution, they are preferably added to the aqueous solution before precipitation has begun. More preferably the seed crystals are added at the meta-stable stage of the crystallization.
- the meta-stable stage of crystallization is defined as the stage at which the solution is saturated but crystallization has not yet begun.
- anhydrous crystalline N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)-3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ mefhyl)acetamide may be isolated by inducing crystallization of a solution of N-( ⁇ (5S)-3-[4-(l,l-dioxido-4-thiomo ⁇ holinyl)- 3,5-difluorophenyl]-2- oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide, wherein the solution includes methanol and methylene chloride.
- the solution includes at least about 2% by weight methanol.
- the solution includes at most about 5% by weight methanol.
- the crystallization may be induced by, for example, cooling the solution.
- the anhydrous crystalline form preferably has a melting point of at least about 170°C, more preferably at least about 180°C, and most preferably at least about 187°C.
- the anhydrous crystalline form is preferably not hygroscopic.
- the anhydrous crystalline form picks up at most about 1% by weight moisture, more preferably at most about 0.5% by weight moisture, and most preferably at most about 0.3% by weight moisture at 90% relative humidity during a dynamic moisture so ⁇ tion scan from 0 to 90% relative humidity at 25°C using 3% humidity steps and an equilibrium time of not more than 180 minutes at each step.
- the anhydrous crystalline form exhibits excellent bulk drug stability in aging tests.
- the anhydrous crystalline form remains stable after storage at elevated temperatures and humidities.
- the anhydrous crystalline form remains stable at 56°C, and more preferably at 70°C, at 70% humidity for two months.
- Solvated forms of the thiazoline oxazolidinone may be isolated by cooling a solution of the thiazine oxazolidinone in an organic solvent.
- the solvate includes the organic solvent.
- the organic solvent is non- halogenated.
- Preferred organic solvents include tetrahydrofuran, acetone, ethyl acetate, acetonitrile, and alcohols.
- the solution may also include water. If water is included, the solution preferably includes at most about 5% by weight water. Preferably the solution includes at least about 2% by weight of the thiazine oxazolidinone.
- compositions of this invention may be prepared by combining the anhydrous crystalline form of the present invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques.
- Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories.
- a solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent.
- Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like.
- Liquid form compositions include solutions, suspensions and emulsions.
- solutions of the anhydrous crystalline form of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
- the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of the active component, that is, the compound of this invention.
- the quantity of active component that is the compound of this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound and the desired concentration. Generally, the quantity of active component is about 0.5% by weight to about 90% by weight of the composition.
- the compounds or its pharmaceutical compositions will be administered orally, topically, transdermally, and/or parenterally at a dosage to obtain and maintain a concentration which will be antibacterially effective.
- such antibacterially effective amount of dosage of active component will be about 0.1 to about 100 mg/kg of body weight/day, and more preferably about 1.0 to about 50 mg/kg of body weight/day.
- the dosages may vary depending upon the requirements of the patient and the severity of the bacterial infection being treated.
- the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.
- compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5 to about 6.
- a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5 to about 6.
- Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N -methyl glue amine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents.
- the compound of the invention generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration of about 1 mg/ml to about 400 mg/ml of solution.
- the resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage.
- the compound of this invention is advantageously administered orally in solid and liquid dosage forms.
- Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
- Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
- Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, mefhanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, (x-ketoglutarate, maleate, fumarate, benzenesulfonate and (X-glycerophosphate.
- Suitable inorganic salts may also be formed, including hydrobromide, hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts. The present invention is illustrated by the following examples.
- X-ray diffraction (XRD) patterns were measured on a Scintag X2 diffractometer (Thermo ARL, Ecublens, Switzerland) equipped with a theta-theta goniometer. Single crystal x-ray diffraction was carried out on a Bruker SMART 6K CCD Area Detector diffractometer (Bruker AXS, Düsseldorf, Germany). Mass spectrometry (MS) (ionization type) was carried out on a Micromass Platform II spectrometer (Micromass, Manchester, United Kingdom).
- HPLC High pressure liquid chromatography
- Agilent 1100 Series chromatograph Agilent Technologies, Palo Alto, CA. Melting points were determined using a TA Instruments 2920 differential scanning calorimeter (TA Instruments, New Castle, DE) module with a Thermal Analyst 5000 controller. Hygroscopicity was assessed by dynamic moisture so ⁇ tion gravimetry (DMSG) using a Controlled Atmosphere Microbalance (Pharmacia Co ⁇ ., Kalamazoo, MI). All chemicals used are available from Aldrich Chemical Co., Milwaukee, WI, unless otherwise specified.
- Powder X-Ray diffraction was performed using a Scintag X2 Advanced Diffraction System operating under Scintag DMS/NT 1.30a and Microsoft Windows NT 4.0 software.
- the system uses a Copper X-Ray source maintained at 45 kV and 40 MA to provide CuK ⁇ emission of 1.5406A and a solid-state Peltier cooled detector.
- the beam aperture was controlled using tube divergence and anti-scatter slits of 2 and 4 mm and detector anti-scatter and receiving slits of 0.5 and 0.2 mm width. Data was collected from 2 to 35° two-theta using a step scan of 0.037point with a one second per step counting time.
- DMSG isotherms were collected on the variable temperature controlled atmospheric microbalance. Approximately 10 mg samples were used in the balance. Samples were run as received. The humidity was sequentially set between 0 and 90 % RH in 3 % RH steps. The mass was then measured every two minutes. The RH was changed to the next value when the mass of the sample was stable to within 0.5 ⁇ g in 480 seconds.
- a Visual Basic program was used to control the data collection and export the information to an Excel spreadsheet.
- DSC Differential Scanning Calorimetry
- Procedure A The 2-propanol solvate as prepared in Example 2 (12.7 g, approximately 6% by weight 2-propanol content) was dissolved in 250 mL of water at 95-100°C. The mixture was cooled at approximately 5°C/hour from 100°C to 80°C and at 10°C/hour from 80°C to 5°C. The mixture was then filtered, and the filtered solid was dried to give 12.1 g of anhydrous crystalline thiazine oxazolidinone.
- Procedure B In THF/water: The 2-propanol solvate as prepared in Example 2 (10 g, approximately 6% by weight 2-propanol content) was dissolved in 50 ml of a liquid containing 25% by volume water and 75% by volume tetrahydrofuran. The above solution was added to 200 mL of water at a rate of 0.8 mL/min at 20-25°C. An agitation rate of 250 ⁇ m or greater was used during the addition. When addition was complete, the mixture was cooled to 0 to 5°C and then filtered. The filtered solid was dried to give 8.2 g of anhydrous crystalline thiazine oxazolidinone.
- Procedure C A methylene chloride solution of the thiazine oxazolidinone (about 7 kg) was distilled at a pressure of 740 to 780 mm Hg while water and methanol were added. The distillation was continued until the vapor temperature reached 85 to 87°C. The final volume was 120 to 160 L. The mixture was then cooled gradually until a temperature of 60 to 62°C was reached, seeded with 35 g of anhydrous thiazine oxazolidinone crystals. When the mixture was at a temperature of 58 to 60°C Intel 35 g of anhydrous thiazine oxazolidinone crystals were again added.
- the mixture was then cooled at a rate of 5°C/hour to a temperature of 0 to 5 °C.
- the slurry was filtered, and the filtered solid was dried to give 5.5 kg of anhydrous crystalline thiazine oxazolidinone.
- Hygroscopicity of the anhydrous crystalline thiazine oxazolidinone was assessed at 25°C and indicated that the material was not hygroscopic, picking up approximately 0.2% moisture during a dynamic moisture so ⁇ tion scan from 0 to 87% relative humidity using 3% humidity steps and an equilibrium time of not more than 180 minutes at each step.
- EXAMPLE 6 Bulk Drug Stability
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002453182A CA2453182A1 (en) | 2001-07-10 | 2002-07-10 | Crystalline thiazine oxazolidinones |
EP02768301A EP1406880A1 (en) | 2001-07-10 | 2002-07-10 | Crystalline thiazine oxazolidinones |
JP2003512213A JP2005502628A (en) | 2001-07-10 | 2002-07-10 | Crystalline thiazine oxazolidinone |
MXPA04000294A MXPA04000294A (en) | 2001-07-10 | 2002-07-10 | Crystalline thiazine oxazolidinones. |
BR0211061-0A BR0211061A (en) | 2001-07-10 | 2002-07-10 | Thiazine oxazolidinones crystals and processes for isolating such crystals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30415701P | 2001-07-10 | 2001-07-10 | |
US60/304,157 | 2001-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003006441A1 true WO2003006441A1 (en) | 2003-01-23 |
Family
ID=23175315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/021779 WO2003006441A1 (en) | 2001-07-10 | 2002-07-10 | Crystalline thiazine oxazolidinones |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030109525A1 (en) |
EP (1) | EP1406880A1 (en) |
JP (1) | JP2005502628A (en) |
BR (1) | BR0211061A (en) |
CA (1) | CA2453182A1 (en) |
MX (1) | MXPA04000294A (en) |
WO (1) | WO2003006441A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102885788A (en) * | 2011-07-22 | 2013-01-23 | 重庆华邦制药股份有限公司 | Linezolid tablets in stable crystal form and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19821665A1 (en) * | 1997-05-28 | 1998-12-03 | Basf Ag | Composite pigment with good fastness to colour bleeding |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007271A1 (en) * | 1993-09-09 | 1995-03-16 | The Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
WO2001098297A2 (en) * | 2000-06-16 | 2001-12-27 | Pharmacia & Up John Company | A thiazine oxazolidinone |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3752A (en) * | 1844-09-20 | peters | ||
US38021A (en) * | 1863-03-31 | Improved method of using exhaust-steam for heating purposes | ||
US45746A (en) * | 1865-01-03 | Improved machine for cutting soap | ||
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
DK0690864T3 (en) * | 1993-03-12 | 2001-09-17 | Upjohn Co | Crystalline ceftiofur in free acid form |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
US5665878A (en) * | 1994-08-31 | 1997-09-09 | Eli Lilly And Company | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives |
DE19503966C2 (en) * | 1995-02-07 | 1998-07-02 | Mack Chem Pharm | Crystal modification of 2,4-diamino-6-hydroxymethylpteridine hydrobromide, process for its preparation and its use |
US6066647A (en) * | 1996-07-29 | 2000-05-23 | Pfizer Inc. | Zwitterionic forms of trovafloxacin |
WO1998029344A1 (en) * | 1996-12-25 | 1998-07-09 | Nippon Kayaku Kabushiki Kaisha | Fine cisplatin powder and process for the production thereof |
EP2404910A3 (en) * | 1998-06-19 | 2014-10-29 | Teijin Pharma Limited | Polymorphs of 2-(3-cyano-4-Isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
US6239141B1 (en) * | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
US6316672B1 (en) * | 2001-01-31 | 2001-11-13 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
-
2002
- 2002-07-10 JP JP2003512213A patent/JP2005502628A/en active Pending
- 2002-07-10 CA CA002453182A patent/CA2453182A1/en not_active Abandoned
- 2002-07-10 MX MXPA04000294A patent/MXPA04000294A/en unknown
- 2002-07-10 WO PCT/US2002/021779 patent/WO2003006441A1/en not_active Application Discontinuation
- 2002-07-10 BR BR0211061-0A patent/BR0211061A/en not_active Application Discontinuation
- 2002-07-10 US US10/193,765 patent/US20030109525A1/en not_active Abandoned
- 2002-07-10 EP EP02768301A patent/EP1406880A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007271A1 (en) * | 1993-09-09 | 1995-03-16 | The Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
WO2001098297A2 (en) * | 2000-06-16 | 2001-12-27 | Pharmacia & Up John Company | A thiazine oxazolidinone |
Non-Patent Citations (1)
Title |
---|
SHEKUNOV B Y ET AL: "Crystallization processes in pharmaceutical technology and drug delivery design", JOURNAL OF CRYSTAL GROWTH, NORTH-HOLLAND PUBLISHING CO. AMSTERDAM, NL, vol. 211, no. 1-4, April 2000 (2000-04-01), pages 122 - 136, XP004193361, ISSN: 0022-0248 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102885788A (en) * | 2011-07-22 | 2013-01-23 | 重庆华邦制药股份有限公司 | Linezolid tablets in stable crystal form and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1406880A1 (en) | 2004-04-14 |
US20030109525A1 (en) | 2003-06-12 |
CA2453182A1 (en) | 2003-01-23 |
JP2005502628A (en) | 2005-01-27 |
MXPA04000294A (en) | 2004-05-04 |
BR0211061A (en) | 2004-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0717738B1 (en) | Substituted oxazine and thiazine oxazolidinone antimicrobials | |
RU2292345C9 (en) | Oxazolidinone derivatives | |
WO2005058886A1 (en) | Novel oxazolidinone derivatives | |
KR20020067557A (en) | Oxazolidinones Having a Sulfoximine Functionality and Their Use as Antimicrobial Agent | |
JP2008530144A (en) | Crystalline form of linezolid intermediate | |
EA004434B1 (en) | Linezolid-crystal form ii | |
RU2463295C2 (en) | Crystalline forms glyt1 | |
KR20010032782A (en) | S-Oxide and S,S-Dioxide Tetrahydrothiopyran Phenyloxazolidinones | |
WO2004009587A1 (en) | Oxazolidinone derivatives as antibacterial agents | |
MX2007012332A (en) | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard. | |
CN105008356A (en) | Solid state forms of vemurafenib hydrochloride | |
EP1406880A1 (en) | Crystalline thiazine oxazolidinones | |
US20150322084A1 (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | |
US8987243B2 (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt | |
JP2005519996A (en) | Method for producing oxazolidinones and method for using the same | |
EP2397473A1 (en) | A stable highly crystalline anacetrapib | |
EP2402355A1 (en) | Crystalline anhydrous forms II and III of Tulathromycin | |
EP4048404A1 (en) | Polymorphs of avapritinib and methods for preparing the polymorphs | |
MXPA02009317A (en) | Novel benzosultam oxazolidinone antibacterial agents. | |
WO2013064188A1 (en) | A stable highly crystalline anacetrapib | |
US20080064727A1 (en) | Crystalline forms of tiagabine hydrochloride | |
JP2018535969A (en) | Solid state form of PDE10 inhibitor | |
OA11955A (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2-2-2-Üoct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as NK-1 receptor antagonists. | |
WO2004101552A1 (en) | Oxazolidinone derivatives as antibacterial agents | |
WO2007092961A2 (en) | Antibacterial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2453182 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003512213 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/000294 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002768301 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004106554 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2002768301 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002768301 Country of ref document: EP |